Elitek (Rasburicase) - Current Clinical Trials

Elitek Related Clinical Trials

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma [Completed]

Rasburicase for Hyperuricemia [Completed]

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma [Terminated]

Fasturtec TLS Treatment / Prophylysis [Completed]

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS [Completed]

Study of Rasburicase Versus Allopurinol in Patients With Leukemia, Lymphoma, or Solid Tumor Malignancy at Risk for Hyperuricemia and Tumor Lysis Syndrome [Active, not recruiting]

Rasburicase in Treating or Preventing High Levels of Uric Acid in the Blood and Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumors [Active, not recruiting]

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy [Completed]

Rasburicase (Fasturtec) Registration Trial [Recruiting]

Rasburicase in Patients at Risk for Tumor Lysis Syndrome [Recruiting]

Rasburicase in Tumor Lysis Syndrome [Active, not recruiting]

Rasburicase to Prevent Acute Kidney Injury Following Cardiac Surgery [Recruiting]

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant [Recruiting]

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome [Completed]

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients [Recruiting]

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma [Recruiting]